Form 4: Xeris Biopharma Holdings Executive Kevin McCulloch Reports Changes in Beneficial Ownership

Kevin McCulloch, President and COO of Xeris Biopharma Holdings, reports a transaction involving common stock due to tax obligations related to vested restricted stock units.

Summary

• On April 2, 2025, Kevin McCulloch, President and COO of Xeris Biopharma Holdings, reported changes in beneficial ownership of the company's common stock.
• 733 shares were withheld by the issuer to cover income tax obligations related to the vesting of restricted stock units at a price of $5.15.
• Following the transaction, McCulloch directly owns 1,683,585 shares of common stock.
• McCulloch also reports indirect ownership of 25,000 shares held by his spouse and 2,000 shares held by the Charles R. McCulloch Trust dated 1990, but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of a routine transaction related to executive compensation. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it relates to tax obligations of vested stock.

Key Dates

Keywords

beneficial ownership, Xeris Biopharma Holdings, Kevin McCulloch, Form 4, common stock, restricted stock units, tax withholding